期刊文献+

尿毒灵治疗慢性肾功能衰竭的临床疗效分析 被引量:1

The Clinical Analysis of Therapeutic Efficaly in the Treatment of Kidey Failure
下载PDF
导出
摘要 目的肾病在我国属多发性疾病,且大多数肾病最终会转变为慢性肾功能衰竭,而慢性肾衰竭的非透析治疗药物是其主要治疗手段之一。针对药物治疗过程中药品种类繁多,没有严格的治疗标准。该文通过对尿毒灵和包醛氧淀粉治疗慢性肾功能衰竭的效果的对比研究,为后续治疗提供临床理论依据。方法该研究采用该院2008年1月—2011年12月肾病专科门诊的200例慢性肾衰竭非透析治疗患者,通过尿毒灵与包醛氧淀粉的治疗效果对比研究得到尿毒灵对慢性肾功能衰竭的临床数据。结果采用尿毒灵治疗的总体有效率为91%,显著高于对照组。结论建议在实际临床治疗过程中推广尿毒灵对慢性肾功能衰竭的应用。 Objective Kidney disease in China with multiple diseases,most of nephropathy with chronic renal failure after the development of the final change.Objective:Chronic renal failure in non-dialysis therapy is one of the main means.For a wide range of drug treatment process of drug,there are no strict standards of care.Starch by the spirit of this article uremic package aldehyde oxygen on the treatment of chronic renal failure compared clinical theoretical basis for follow-up treatment.Methods 200 cases of our hospital from January 2008 to December 2011 kidney specialist outpatient chronic renal failure in patients with non-dialysis uremic spirit with packages starch aldehyde oxygen therapy study on the effect the uremic Spirit of chronic renal failure clinical data.Results The found uremic spiritual treatment of the overall effective rate was 91%,significantly higher than.Conclusion It is recommended that the application to promote the of uremic spirit with chronic renal failure in the actual clinical course of treatment.
作者 刘新君
出处 《中外医疗》 2012年第26期31-32,共2页 China & Foreign Medical Treatment
关键词 尿毒灵 慢性肾功能衰竭 临床对比 包醛氧淀粉 NiaoduLing Uremic chronic renal failure Clinical comparison Package aldehyde oxygen starch
  • 相关文献

参考文献2

二级参考文献15

  • 1林秀珍,马德禄,崔荣芬.大黄素及番泻甙和大黄多糖对培养大鼠肝细胞内游离钙浓度的影响[J].中国中西医结合杂志,1995,15(7):419-421. 被引量:37
  • 2张国强,叶任高,陈永雄,孔庆瑜,关伟明.间质纤维化人肾成纤维细胞的异常生长及凋亡[J].肾脏病与透析肾移植杂志,1996,5(3):5-8. 被引量:9
  • 3张群豪 陈可冀.血清药理学在中药及复方研究中应用的评价[J].中国中西医结合杂志,1996,16(3):131-131.
  • 4Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int, 1999,56(5):1627 - 1637.
  • 5Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2000,414 (6865) : 813 - 820.
  • 6Ichimura T,Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule- 1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest, 2008,118 (5) : 1657 - 1668.
  • 7Lee HB, Ha H. Piasminogen activator inhibitor - 1 and diabetic nephropathy. Nephrology, 2005,10 (Suppl) : S11 - S13.
  • 8Eddy AA, Fogo AB. Plasminogen activator inhibitor - 1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol,2006,17(11) :2999 - 3012.
  • 9Rerolle JP, Hertig A, Ngugen G, et al. Plasminongen activatior inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int,2000,58(5) : 1841 - 1850.
  • 10牟姗,倪兆慧,张庆怡.高糖诱导人肾间质成纤维细胞c-met的表达及黄芪对其的调节作用[J].中西医结合学报,2008,6(5):482-487. 被引量:12

共引文献86

同被引文献6

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部